Study: Pregnancy drug use decades ago is raising daughters’ risks of cancer, infertility now

Study: Pregnancy drug use decades ago is raising daughters’ risks of cancer, infertility now
By Associated Press, Published: October 5

A drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds.

Many of these daughters, now over 40, may not even know of their risk if their mothers never realized or told them they had used the drug, a synthetic estrogen called DES.

Debbie Wingard in her office at the University of California-San Diego where she is a professor. Wingard has had breast cancer twice and has been unable to conceive which she believes is due to her mother’s use of the drug DES during pregnancy. The drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds.

Jackie White in Branchville, N.J. White, a breast cancer survivor and a DES daughter who lives in Centerburg, Ohio, north of Columbus, said she had a misshaped uterus and reproductive problems, and found a lump last year that turned out to be breast cancer. Tests showed 20 tumors in one breast, two pre-cancers in the other and spread to her lymph nodes. The drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds.

The new study suggests that infertility is twice as common and that breast cancer risk is nearly doubled in these daughters.

Debbie Wingard is one of them. The 59-year-old San Diego woman adopted two boys after being unable to conceive and has had breast cancer twice — when she was 39 and 49.

“There’s no knowing what’s going to happen as we age. There’s always the fear there’s going to be another cancer or another outcome,” she said. “I don’t think I’ll ever get to the point where I feel it’s behind me.”

The sons of DES users also face health risks — testicular problems and cysts — but these are less well studied and don’t seem to be as common. Even less is known about the third generation — “DES grandchildren.” Some research suggests these girls start menstruating late and have irregular periods, possible signs of fertility issues down the road.

In the United States alone, more than 2 million women and 2 million men are thought to have been exposed to DES while in the womb and may now want to talk with their doctors about when they should be screened for health problems.

“We don’t want to cause a panic of everyone rushing out thinking they’re going to get cervical or breast cancer. They just need to have that conversation with their physician,” said Dr. Sharmila Makhija, women’s health chief at the University of Louisville.

The average woman has about a 1 in 50 chance of developing breast cancer by age 55; for DES daughters it’s 1 in 25, the study found. Risks for other health problems vary.

DES, or diethylstilbestrol, was widely used in the United States, Europe and elsewhere from the 1940s through the 1960s to prevent miscarriage, premature birth, bleeding and other problems. Many companies made and sold it as pills, creams and other forms.

Studies later showed it didn’t work. The government told doctors to stop using it in pregnancy in 1971, after DES daughters in their late teens and 20s were found to be at higher risk of a rare form of vaginal cancer. Further research has tied DES to infertility and various pregnancy problems.

“They’ve been identified one at a time. Nobody’s been able to get the whole picture,” said Dr. Robert Hoover, a researcher at the National Cancer Institute. The new study, which he led, “takes the woman and looks at everything that can happen as a result of this drug,” and adds evidence for some previously suspected risks like breast cancer, he said.

Results are in Thursday’s New England Journal of Medicine.

The study started in 1992 and involved about 4,600 DES daughters and a comparison group of 1,900 similar women whose mothers had not used DES. Their health was tracked over time through surveys and medical records. Their average age at the last followup was 48.